Kevin Bitter Email & Phone Number

Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate OPT-302 is in pivotal Phase 3 clinical trials and being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the goal of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.

Primary responsibilities as direct report to CEO: global business development (in- and out-licensing), strategic partnerships, post-transaction integration, portfolio strategy and business planning, investor communications, special projects for executive leadership team and Board of Directors.Graybug was a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. (Graybug merged with CalciMedica, a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need.)

Primary responsibilities as direct report to CFO: long-range financial planning and scenario modeling, international joint venture structuring (Germany), portfolio strategy, business development, investor relations and roadshows, private debt structuring and public debt/equity financings.Corium is a commercial-stage biopharmaceutical company focused on the development, manufacture, and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems.